Osteoporosis New Zealand (ONZ) is delighted to advise that Pharmac has decided to fund denosumab (Prolia) in NZ for the treatment of severe, established osteoporosis, subject to certain clinical criteria being met.
Denosumab (Prolia) will be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 July 2018.

The details of this decision can be found here.